Virtu Financial LLC Acquires New Position in Fractyl Health, Inc. (NASDAQ:GUTS)

Virtu Financial LLC bought a new position in shares of Fractyl Health, Inc. (NASDAQ:GUTS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 33,462 shares of the company’s stock, valued at approximately $85,000. Virtu Financial LLC owned 0.07% of Fractyl Health at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of GUTS. BNP Paribas Financial Markets increased its holdings in shares of Fractyl Health by 54.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock worth $53,000 after buying an additional 7,397 shares during the last quarter. Rhumbline Advisers purchased a new position in Fractyl Health in the second quarter worth approximately $32,000. Jane Street Group LLC acquired a new stake in Fractyl Health during the third quarter worth $25,000. SG Americas Securities LLC purchased a new stake in Fractyl Health in the third quarter valued at $33,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Fractyl Health in the 2nd quarter valued at $61,000.

Fractyl Health Stock Performance

NASDAQ GUTS opened at $1.82 on Friday. The stock has a fifty day simple moving average of $2.38 and a 200-day simple moving average of $3.23. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The stock has a market cap of $87.54 million and a PE ratio of -0.15. Fractyl Health, Inc. has a twelve month low of $1.74 and a twelve month high of $14.50.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter. Equities analysts anticipate that Fractyl Health, Inc. will post -1.66 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Jay David Caplan sold 64,197 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $158,566.59. Following the transaction, the insider now owns 153,544 shares of the company’s stock, valued at approximately $379,253.68. This represents a 29.48 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Harith Rajagopalan sold 96,517 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $238,396.99. Following the transaction, the chief executive officer now owns 491,329 shares of the company’s stock, valued at $1,213,582.63. This trade represents a 16.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.